Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is effective in patients with advanced B-cell acute lymphoblastic leukemia (B-ALL). However, efficacy data is sparse in subgroups of patients with high-risk features such as BCR-ABL+, TP53 mutation, extramedullary disease (including central ne...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood advances 2020-05, Vol.4 (10), p.2325-2338
Hauptverfasser:	Zhang, Xian, Lu, Xin-an, Yang, Junfang, Zhang, Gailing, Li, Jingjing, Song, Lisong, Su, Yunchao, Shi, Yanze, Zhang, Min, He, Jiujiang, Song, Dan, Lv, Fanyong, Li, Wenqian, Wu, Yan, Wang, Hui, Liu, Hongxing, Zhou, Xiaosu, He, Ting, Lu, Peihua
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Antigens, CD19 B-Lymphocytes Child Child, Preschool Hematology Hematopoietic Stem Cell Transplantation Humans Immunobiology and Immunotherapy Immunotherapy, Adoptive Life Sciences & Biomedicine Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!